The Effectiveness of NeuroStar TMS Therapy
While exploring new treatment options for depression, people often wonder about the overall effectiveness of a given treatment. NeuroStar Advanced Therapy (TMS) is approved by the Food and Drug Administration (FDA), but that approval alone does not paint a picture of the effectiveness of the treatment. In this post, we will walk you through how the treatment works and what it offers to patients suffering from chronic depression.
NeuroStar TMS Therapy Effectiveness
Recently, a NIMH-funded, randomized controlled trial treated individuals suffering from depression using the NeuroStar TMS Therapy. Patients treated in the trial were four times more likely to experience remission. For many, the symptoms of depression improved or disappeared within 4-6 weeks after treatment with NeuroStar.
Furthermore, TMS therapy managed to achieve long-term durability over 12 months. What does this mean for patients? After undergoing therapy sessions, the results remain steady for an entire year. After that period, you may need to undergo another round of therapy sessions.
Now, that may sound tedious to some, but look at it like this; for one month of treatment, you’ll receive an entire year of improved mental health. It’s an investment in your overall well-being; one that has profound results for individuals suffering from depression.
During this 12-month period, only 1 in 3 patients required maintenance sessions or ‘reintroduction’.
Individuals suffering from depression typically exhaust every treatment option over time. Medications, therapy, and natural treatments often do not work. Where antidepressant medications fail, TMS Therapy has become the go-to option. According to guidelines from the 2010 American Psychiatric Association’s guidelines and NeuroStar TMS Therapy:
“NeuroStar TMS Therapy is indicated for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication at or above the minimal effective dose and duration in the current episode.”